These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28091972)

  • 21. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].
    Riva L; Di Pasquale G; Casella G; Calabrese D; Zagnoni S; Pallotti MG
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 3):27S-33S. PubMed ID: 21491737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
    Roe MT; Cyr DD; Eckart D; Schulte PJ; Morse MA; Blackwell KL; Ready NE; Zafar SY; Beaven AW; Strickler JH; Onken JE; Winters KJ; Houterloot L; Zamoryakhin D; Wiviott SD; White HD; Prabhakaran D; Fox KA; Armstrong PW; Ohman EM;
    Eur Heart J; 2016 Jan; 37(4):412-22. PubMed ID: 26637834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiplatelet therapy in acute coronary syndrome and atrial fibrillation: aspirin.
    Tanguay JF
    Adv Cardiol; 2012; 47():20-30. PubMed ID: 22906900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
    Gargiulo G; Windecker S; Vranckx P; Gibson CM; Mehran R; Valgimigli M
    Circulation; 2016 Dec; 134(23):1881-1906. PubMed ID: 27920074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
    Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
    Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
    Cornel JH; Ohman EM; Neely B; Jakubowski JA; Bhatt DL; White HD; Ardissino D; Fox KA; Prabhakaran D; Armstrong PW; Erlinge D; Tantry US; Gurbel PA; Roe MT
    J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27815268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
    Becker RC; Gibson CM; Jennings LK; Morrow DA
    Am J Cardiol; 2010 Oct; 106(8):S2-3. PubMed ID: 20920638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations.
    Fitchett DH; Goodman SG; Leiter LA; Lin P; Welsh R; Stone J; Grégoire J; Mcfarlane P; Langer A
    Can J Cardiol; 2016 Jul; 32(7 Suppl):S15-34. PubMed ID: 27342696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome.
    White H
    Clin Appl Thromb Hemost; 2014 Jul; 20(5):516-23. PubMed ID: 23344993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Patients with non-ST-elevation acute coronary syndrome managed without coronary revascularization: an undertreated population].
    Menozzi A; De Luca L; Olivari Z; Rossini R; Ferlini M; Lina D; Abrignani MG; Capranzano P; Carrabba N; Galvani M; Marchese A; Mazzotta G; Moretti L; Signore N; Uguccioni M; De Servi S
    G Ital Cardiol (Rome); 2016 Oct; 17(10):816-826. PubMed ID: 27869899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
    Islam AM; Patel PM
    J Cardiovasc Pharmacol; 2010 Jun; 55(6):585-94. PubMed ID: 20224426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bleeding in patients receiving dual antiplatelet therapy after acute coronary syndrome - significance, prevention and interdisciplinary management].
    Zeymer U; Koscielny J; von Heymann C; Spannagl M; Labenz J; Cremer J; Giannitsis E; Darius H; Goss F
    Dtsch Med Wochenschr; 2016 Jul; 141(15):1107-11. PubMed ID: 27464285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
    Chiang FT; Shyu KG; Wu CJ; Mar GY; Hou CJ; Li AH; Wen MS; Lai WT; Lin SJ; Kuo CT; Kuo C; Li YH; Hwang JJ;
    J Formos Med Assoc; 2014 Nov; 113(11):794-802. PubMed ID: 24076272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.